Literature DB >> 30849700

Why recombinant antibodies - benefits and applications.

Koli Basu1, Evan M Green2, Yifan Cheng3, Charles S Craik1.   

Abstract

Antibodies (Abs) are ubiquitous reagents for biological and biochemical research and are rapidly expanding into new therapeutic areas. They are one of the most important probes for determining how proteins function under normal and pathophysiological conditions. Abs are required for the quantification of targets, detection of temporal and spatial patterns of protein expression in cells and tissues, and identification of interacting partners and their biological activities. Their remarkable specificity and unique binding properties can facilitate three-dimensional structure determination using X-ray crystallography and electron cryomicroscopy. While hybridoma technology that involves animal immunization is often productive, many antigen targets do not generate useful Abs. This is particularly true if unique states of the target or critical non-immunogenic target sequences need to be recognized by the Abs. By using the methods of recombinant antibody generation, identification, and engineering, these 'hybridoma-refractory' antigens can be readily targeted. Specific, reproducible, and renewable recombinant Abs are proving to be invaluable reagents in applications ranging from biological discovery to structure determination of challenging macromolecules.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30849700      PMCID: PMC6728236          DOI: 10.1016/j.copbio.2019.01.012

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  58 in total

Review 1.  Antibody phage display technology and its applications.

Authors:  H R Hoogenboom; A P de Bruïne; S E Hufton; R M Hoet; J W Arends; R C Roovers
Journal:  Immunotechnology       Date:  1998-06

2.  A reverse binding motif that contributes to specific protease inhibition by antibodies.

Authors:  Eric L Schneider; Melody S Lee; Aida Baharuddin; David H Goetz; Christopher J Farady; Mick Ward; Cheng-I Wang; Charles S Craik
Journal:  J Mol Biol       Date:  2011-11-27       Impact factor: 5.469

3.  Imaging a functional tumorigenic biomarker in the transformed epithelium.

Authors:  Aaron M LeBeau; Minhee Lee; Stephanie T Murphy; Byron C Hann; Robert S Warren; Romelyn Delos Santos; John Kurhanewicz; Samir M Hanash; Henry F VanBrocklin; Charles S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

4.  Selection of phage antibodies by binding affinity. Mimicking affinity maturation.

Authors:  R E Hawkins; S J Russell; G Winter
Journal:  J Mol Biol       Date:  1992-08-05       Impact factor: 5.469

5.  By-passing immunization: building high affinity human antibodies by chain shuffling.

Authors:  J D Marks; A D Griffiths; M Malmqvist; T P Clackson; J M Bye; G Winter
Journal:  Biotechnology (N Y)       Date:  1992-07

6.  Cryo-EM structure of human rhodopsin bound to an inhibitory G protein.

Authors:  Yanyong Kang; Oleg Kuybeda; Parker W de Waal; Somnath Mukherjee; Ned Van Eps; Przemyslaw Dutka; X Edward Zhou; Alberto Bartesaghi; Satchal Erramilli; Takefumi Morizumi; Xin Gu; Yanting Yin; Ping Liu; Yi Jiang; Xing Meng; Gongpu Zhao; Karsten Melcher; Oliver P Ernst; Anthony A Kossiakoff; Sriram Subramaniam; H Eric Xu
Journal:  Nature       Date:  2018-06-13       Impact factor: 49.962

7.  A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4.

Authors:  Anna Moroz; Chia-Yin Lee; Yung-Hua Wang; Jeffrey C Hsiao; Natalia Sevillano; Charles Truillet; Charles S Craik; Lawrence Fong; Cheng-I Wang; Michael J Evans
Journal:  Bioconjug Chem       Date:  2018-09-24       Impact factor: 4.774

8.  Yeast surface display platform for rapid discovery of conformationally selective nanobodies.

Authors:  Conor McMahon; Alexander S Baier; Roberta Pascolutti; Marcin Wegrecki; Sanduo Zheng; Janice X Ong; Sarah C Erlandson; Daniel Hilger; Søren G F Rasmussen; Aaron M Ring; Aashish Manglik; Andrew C Kruse
Journal:  Nat Struct Mol Biol       Date:  2018-02-12       Impact factor: 15.369

9.  Structure of a human synaptic GABAA receptor.

Authors:  Shaotong Zhu; Colleen M Noviello; Jinfeng Teng; Richard M Walsh; Jeong Joo Kim; Ryan E Hibbs
Journal:  Nature       Date:  2018-06-27       Impact factor: 49.962

10.  A synthetic intrabody-based selective and generic inhibitor of GPCR endocytosis.

Authors:  Eshan Ghosh; Ashish Srivastava; Mithu Baidya; Punita Kumari; Hemlata Dwivedi; Kumari Nidhi; Ravi Ranjan; Shalini Dogra; Akiko Koide; Prem N Yadav; Sachdev S Sidhu; Shohei Koide; Arun K Shukla
Journal:  Nat Nanotechnol       Date:  2017-10-02       Impact factor: 39.213

View more
  9 in total

1.  Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins.

Authors:  Joël S Bloch; Somnath Mukherjee; Julia Kowal; Ekaterina V Filippova; Martina Niederer; Els Pardon; Jan Steyaert; Anthony A Kossiakoff; Kaspar P Locher
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 11.205

2.  Immunotargeting of Nanocrystals by SpyCatcher Conjugation of Engineered Antibodies.

Authors:  Cassio C S Pedroso; Victor R Mann; Kathrin Zuberbühler; Markus-Frederik Bohn; Jessica Yu; Virginia Altoe; Charles S Craik; Bruce E Cohen
Journal:  ACS Nano       Date:  2021-10-25       Impact factor: 18.027

Review 3.  Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.

Authors:  Hilal Ahmed Parray; Shivangi Shukla; Sweety Samal; Tripti Shrivastava; Shubbir Ahmed; Chandresh Sharma; Rajesh Kumar
Journal:  Int Immunopharmacol       Date:  2020-05-27       Impact factor: 4.932

Review 4.  Peptides, Antibodies, Peptide Antibodies and More.

Authors:  Nicole Trier; Paul Hansen; Gunnar Houen
Journal:  Int J Mol Sci       Date:  2019-12-13       Impact factor: 5.923

5.  Antibody design using LSTM based deep generative model from phage display library for affinity maturation.

Authors:  Koichiro Saka; Taro Kakuzaki; Shoichi Metsugi; Daiki Kashiwagi; Kenji Yoshida; Manabu Wada; Hiroyuki Tsunoda; Reiji Teramoto
Journal:  Sci Rep       Date:  2021-03-12       Impact factor: 4.379

Review 6.  Potential Applications of Fluorescence-Activated Cell Sorting (FACS) and Droplet-Based Microfluidics in Promoting the Discovery of Specific Antibodies for Characterizations of Fish Immune Cells.

Authors:  Chenjie Fei; Li Nie; Jianhua Zhang; Jiong Chen
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

Review 7.  Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives.

Authors:  Izabella de Macedo Henrique; Flavia Sacerdoti; Raissa Lozzardo Ferreira; Camila Henrique; Maria Marta Amaral; Roxane Maria Fontes Piazza; Daniela Luz
Journal:  Front Cell Infect Microbiol       Date:  2022-02-10       Impact factor: 5.293

Review 8.  Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective.

Authors:  Hamideh Raeisi; Masoumeh Azimirad; Ali Nabavi-Rad; Hamid Asadzadeh Aghdaei; Abbas Yadegar; Mohammad Reza Zali
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

Review 9.  Advances in methods for atomic resolution macromolecular structure determination.

Authors:  Michael C Thompson; Todd O Yeates; Jose A Rodriguez
Journal:  F1000Res       Date:  2020-07-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.